858 Therapeutics Announces $50 Million Series B Financing
26 Sep 2024 //
BUSINESSWIRE
858 Therapeutics to Present Preclinical Data on ETX-19477 at the AACR
14 Mar 2024 //
BUSINESSWIRE
858 laid off select researchers, closed New York site
16 Nov 2023 //
FIERCE BIOTECH
858 Therapeutics Expands Board of Directors and Leadership Team
05 Apr 2022 //
BUSINESSWIRE